Search
Agenus Inc
AGENAdd to Watchlist
3.490USD
+0.080+2.35%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
134.44MMarket Cap
1.69P/E TTM
More Details of Agenus Inc Company
Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Agenus Inc Info
Ticker SymbolAGEN
Company nameAgenus Inc
IPO dateFeb 04, 2000
CEOArmen (Garo H)
Number of employees316
Security typeOrdinary Share
Fiscal year-endFeb 04
Address3 Forbes Rd
CityLEXINGTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02421-7305
Phone17816744400
Websitehttps://agenusbio.com/
Ticker SymbolAGEN
IPO dateFeb 04, 2000
CEOArmen (Garo H)
Company Executives of Agenus Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas L. (Tom) Harrison, Ph.D.
Mr. Thomas L. (Tom) Harrison, Ph.D.
Independent Director
Independent Director
39.00K
+23.66%
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+67.22%
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Wright (Timothy R)
Wright (Timothy R)
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Jennifer S. Buell, Ph.D.
Dr. Jennifer S. Buell, Ph.D.
Director
Director
--
--
Ms. Susan F. Hirsch
Ms. Susan F. Hirsch
Independent Director
Independent Director
--
--
Dr. Steven O'Day, M.D.
Dr. Steven O'Day, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Richard Goldberg
Mr. Richard Goldberg
Chief Development Officer
Chief Development Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas L. (Tom) Harrison, Ph.D.
Mr. Thomas L. (Tom) Harrison, Ph.D.
Independent Director
Independent Director
39.00K
+23.66%
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+67.22%
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Wright (Timothy R)
Wright (Timothy R)
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Jennifer S. Buell, Ph.D.
Dr. Jennifer S. Buell, Ph.D.
Director
Director
--
--
FAQs
Who are the top five shareholders of Agenus Inc?
The top five shareholders of Agenus Inc are: Mr. Thomas L. (Tom) Harrison, Ph.D.
How many institutions hold shares of Agenus Inc (AGEN)?
As of 2026Q1, 275 institutions hold shares of Agenus Inc, with a combined market value of approximately 10.91M, accounting for 26.27% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -968401.00.
What is the biggest source of revenue for Agenus Inc?
In 2026Q1, the Non-cash royalty revenue business generated the highest revenue for Agenus Inc, amounting to 108.59M and accounting for 95.09% of total revenue.